Literature DB >> 3487581

B lymphocytes are required for the generation of T cells that mediate healing of cutaneous leishmaniasis.

P Scott, P Natovitz, A Sher.   

Abstract

The role that B lymphocytes and/or antibodies play in the healing of Leishmania major infections in genetically resistant C3H/HeN mice was investigated by monitoring the course of infection in animals that had been B cell depleted by treatment from birth with anti-IgM sera (mu-suppressed). L. major infection of mu-suppressed C3H/HeN mice produced lesions that were significantly larger than those induced in control animals, and failed to heal. Moreover, vaccinated mu-suppressed mice also developed chronic nonhealing infections, although their lesions were initially smaller than those developed by nonvaccinated mu-suppressed controls. The enhanced susceptibility of mu-suppressed mice could be completely overcome by adoptive transfer of T lymphocytes from mice that had spontaneously healed their lesions, and to a lesser extent by T lymphocytes from normal animals. Anti-leishmanial antibody responses were completely absent in mu-suppressed mice, regardless of whether they were lymphocyte reconstituted, whereas delayed type hypersensitivity (DTH) to leishmanial antigens was present in normal and mu-suppressed animals. The ability of immune T cells to protect mu-suppressed mice without restoring humoral responsiveness clearly indicates that antibodies are not necessary for healing leishmanial infections. Instead, the observed effect of mu-suppression argues that B lymphocytes are required for the generation of an effector T cell population, apparently unrelated to DTH, which mediates the healing of cutaneous lesions. These results thus provide the first evidence for the B cell and/or Ig dependency of a T cell population that is critical for the development of immunity against a microbial agent.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3487581

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  B cells modulate T cells so as to favour T helper type 1 and CD8+ T-cell responses in the acute phase of Trypanosoma cruzi infection.

Authors:  Fabiola Cardillo; Edilberto Postol; Jorge Nihei; Luiz S Aroeira; Auro Nomizo; José Mengel
Journal:  Immunology       Date:  2007-07-16       Impact factor: 7.397

2.  Promotion of a functional B cell germinal center response after Leishmania species co-infection is associated with lesion resolution.

Authors:  Katherine N Gibson-Corley; Paola M Boggiatto; Marie M Bockenstedt; Christine A Petersen; Thomas J Waldschmidt; Douglas E Jones
Journal:  Am J Pathol       Date:  2012-03-17       Impact factor: 4.307

3.  Effect of CD4 monoclonal antibody in vivo on lesion development, delayed-type hypersensitivity and interleukin 3 production in experimental murine cutaneous leishmaniasis.

Authors:  F Y Liew; S Millott; R Lelchuk; S Cobbold; H Waldmann
Journal:  Clin Exp Immunol       Date:  1989-03       Impact factor: 4.330

4.  Effect of neonatal injection with antibodies to Leishmania mexicana on its growth in adult infected mice.

Authors:  R M Gorczynski
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

5.  T cell source of type 1 cytokines determines illness patterns in respiratory syncytial virus-infected mice.

Authors:  Y W Tang; B S Graham
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

6.  Pathogenic role of B cells and antibodies in murine Leishmania amazonensis infection.

Authors:  Nanchaya Wanasen; Lijun Xin; Lynn Soong
Journal:  Int J Parasitol       Date:  2007-09-20       Impact factor: 3.981

7.  Human T-cell activation by 14- and 18-kilodalton nuclear proteins of Leishmania infantum.

Authors:  I Suffia; J F Quaranta; M C Eulalio; B Ferrua; P Marty; Y Le Fichoux; J Kubar
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

8.  Membrane glycoprotein M-2 protects against Leishmania amazonensis infection.

Authors:  J Champsi; D McMahon-Pratt
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

9.  Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis.

Authors:  F P Heinzel; M D Sadick; S S Mutha; R M Locksley
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

10.  Differential production of macrophage inflammatory protein 1gamma (MIP-1gamma), lymphotactin, and MIP-2 by CD4(+) Th subsets polarized in vitro and in vivo.

Authors:  Kerstin Müller; Susanne Bischof; Frank Sommer; Michael Lohoff; Werner Solbach; Tamás Laskay
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.